SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.